

# Blood-Based Analyses of Cancer: Circulating Tumor Cells

Cancer Discovery

4, 650-661

DOI: [10.1158/2159-8290.cd-13-1014](https://doi.org/10.1158/2159-8290.cd-13-1014)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Predictive value of epigenetic alterations in head and neck squamous cell carcinoma. <i>Molecular and Cellular Oncology</i> , 2014, 1, e954827.	0.3	15
2	Predicting response to androgen receptor signalling inhibition. <i>Nature Reviews Urology</i> , 2014, 11, 433-435.	1.9	3
3	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
4	Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3470-3471.	0.8	23
5	Escaping Out of the Brain. <i>Cancer Discovery</i> , 2014, 4, 1259-1261.	7.7	12
6	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. <i>Nature Communications</i> , 2014, 5, 5006.	5.8	149
7	Translational research in oncologyâ€”10 years of progress and future prospects. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 649-662.	12.5	65
8	Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cellâ€™s Journey. <i>Cancer Microenvironment</i> , 2014, 7, 117-131.	3.1	54
9	Isolation and enrichment of low abundant particles with insulator-based dielectrophoresis. <i>Biomicrofluidics</i> , 2015, 9, 064113.	1.2	34
10	Toward High-Precision Genomic Biomarkers. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1237-1239.	0.5	1
11	Integrated EpCAMâ€independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. <i>Clinical and Translational Medicine</i> , 2015, 4, 38.	1.7	51
12	SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0142273.	1.1	30
13	Biobanking metastases and biopsy specimens for personalized medicine. <i>Journal of Biorepository Science for Applied Medicine</i> , 2015, , 57.	0.2	2
14	Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 357-371.	0.2	8
15	<i>Ex Vivo</i> Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. <i>Cancer Research</i> , 2015, 75, 2411-2415.	0.4	95
16	Monitoring Trastuzumab Resistance and Cardiotoxicity. <i>Advances in Clinical Chemistry</i> , 2015, 70, 95-130.	1.8	14
17	Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials. , 2015, , 19-37.		0
18	From Mutational Mechanisms in Single Cells to Mutational Patterns in Cancer Genomes. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2015, 80, 117-137.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 177-186.	5.1	240
20	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 191-210.	2.7	20
21	Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. <i>Biomaterials</i> , 2015, 65, 93-102.	5.7	70
22	Tumorigenesis: it takes a village. <i>Nature Reviews Cancer</i> , 2015, 15, 473-483.	12.8	469
23	Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 473-489.	1.0	50
24	Biomarker development in the context of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 295-301.	0.8	20
25	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 41-50.	0.8	75
26	Emerging circulating biomarkers in glioblastoma: promises and challenges. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1311-1323.	1.5	60
27	Biobanking for Personalized Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2015, 864, 55-68.	0.8	41
28	Accessing Genetic Information with Liquid Biopsies. <i>Trends in Genetics</i> , 2015, 31, 564-575.	2.9	121
29	Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1491-1504.	1.5	42
30	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. <i>Cancer Cell</i> , 2015, 28, 666-676.	7.7	700
31	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2015, 5, 1271-1281.	7.7	162
32	Biobanking in the 21st Century. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	8
34	Personalized Approaches to Gastrointestinal Cancers. <i>Surgical Clinics of North America</i> , 2015, 95, 1081-1094.	0.5	5
35	Medical Approach to Wellness. , 2015, , 1-12.		0
36	Role of circulating-tumor DNA analysis in non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 128-134.	0.9	80
37	Molecular Determinants of Radiation Response in Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2015, 25, 67-77.	1.0	8

#	ARTICLE	IF	CITATIONS
38	Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. <i>Translational Lung Cancer Research</i> , 2016, 5, 455-465.	1.3	79
39	Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. <i>Oncotarget</i> , 2016, 7, 48625-48643.	0.8	53
40	New blood markers detection technology: A leap in the diagnosis of gastric cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 1202.	1.4	36
41	Enumeration and targeted analysis of <i>KRAS</i> , <i>BRAF</i> and <i>PIK3CA</i> mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 85349-85364.	0.8	79
42	Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer. <i>Chonnam Medical Journal</i> , 2016, 52, 151.	0.5	19
43	Liquid Biopsy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2016, 3, 69.	1.2	48
44	Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection. <i>Cancers</i> , 2016, 8, 61.	1.7	12
45	Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 269-274.	2.0	40
46	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	3.3	90
47	A liquid biopsy for cancer immunotherapy. <i>Nature Medicine</i> , 2016, 22, 340-341.	15.2	21
48	Genetic traits for hematogeneous tumor cell dissemination in cancer patients. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 41-48.	2.7	20
49	Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors. <i>Cancer Letters</i> , 2016, 376, 347-359.	3.2	21
50	Cell-free circulating tumor DNA in cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 36.	4.9	119
51	CTCs in early breast cancer: A path worth taking. <i>Cancer Letters</i> , 2016, 376, 205-210.	3.2	28
52	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
53	Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 241-252.	1.1	38
54	Ratiometric electrochemiluminescence detection of circulating tumor cells and cell-surface glycans. <i>Journal of Electroanalytical Chemistry</i> , 2016, 781, 48-55.	1.9	26
55	High Performance, Multiplexed Lung Cancer Biomarker Detection on a Plasmonic Gold Chip. <i>Advanced Functional Materials</i> , 2016, 26, 7994-8002.	7.8	84

#	ARTICLE	IF	CITATIONS
56	Monitoring <i>EGFR</i> T790M with plasma DNA from lung cancer patients in a prospective observational study. <i>Cancer Science</i> , 2016, 107, 162-167.	1.7	67
57	Pathologists and liquid biopsies: to be or not to be?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 601-609.	1.4	49
58	Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 173-182.	2.7	19
59	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , 2016, 76, 5954-5961.	0.4	16
60	Are Liquid Biopsies Ready for Prime Time of Clinical Applications?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1606-1608.	0.5	1
61	Affinity Versus Label-Free Isolation of Circulating Tumor Cells: Who Wins?. <i>Small</i> , 2016, 12, 4450-4463.	5.2	90
62	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 5564-5573.	3.2	108
63	Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology. <i>International Journal of Oncology</i> , 2016, 49, 2088-2104.	1.4	4
64	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 490-501.	0.8	11
65	Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. <i>Molecular Oncology</i> , 2016, 10, 1575-1584.	2.1	61
66	Best Practices in Treatment Selection for Patients with Advanced NSCLC. <i>Cancer Control</i> , 2016, 23, 2-14.	0.7	7
67	The biology of circulating tumor cells. <i>Oncogene</i> , 2016, 35, 1216-1224.	2.6	421
68	Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. <i>British Journal of Cancer</i> , 2016, 114, 138-145.	2.9	81
69	Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 464-474.	2.1	101
70	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. <i>Molecular Oncology</i> , 2016, 10, 635-643.	2.1	131
71	Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). <i>Analyst, The</i> , 2016, 141, 393-402.	1.7	23
72	A liquid biopsy for head and neck cancers. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 165-172.	1.5	39
73	The Clinical Utility of Circulating Tumor Cells: Analysis of These Cells May Have the Potential to Assist with Screening and Diagnosing Cancer. <i>IEEE Pulse</i> , 2016, 7, 27-29.	0.1	0

#	ARTICLE	IF	CITATIONS
74	Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 33-68.	0.8	34
75	Use of cell free DNA in breast oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 266-274.	3.3	24
76	CTCs for Biomarker and Companion Diagnostic Development. <i>Current Cancer Research</i> , 2016, , 293-313.	0.2	0
77	Genetics and biology of pancreatic ductal adenocarcinoma. <i>Genes and Development</i> , 2016, 30, 355-385.	2.7	416
78	The “Liquid Biopsy” the Role of Circulating DNA and RNA in Central Nervous System Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 25.	2.0	34
79	An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood. <i>Biomedical Microdevices</i> , 2016, 18, 22.	1.4	23
80	Lung cancer screening: utility of molecular applications in conjunction with low-dose computed tomography guidelines. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 435-447.	1.5	14
81	Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 789-799.	1.1	34
82	Making cancer visible “ Dyes in surgical oncology. <i>Surgical Oncology</i> , 2016, 25, 30-36.	0.8	10
83	Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , .	0.2	6
84	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. <i>Cancer Discovery</i> , 2016, 6, 479-491.	7.7	1,087
85	Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. <i>Current Oncology Reports</i> , 2016, 18, 3.	1.8	22
86	Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics. <i>Analyst, The</i> , 2016, 141, 382-392.	1.7	74
87	Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 25-38.	1.5	30
88	Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. <i>Analyst, The</i> , 2016, 141, 450-460.	1.7	175
89	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	0.9	40
90	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1123-1128.	3.3	133
91	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , 2017, 183, 137-154.	2.2	14

#	ARTICLE	IF	CITATIONS
92	Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 158-165.	1.5	190
93	Milestones in pathologyâ€”from histology to molecular biology. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 42-45.	0.3	7
94	Integrating liquid biopsies into the management of cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 531-548.	12.5	1,375
95	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. <i>Cell</i> , 2017, 168, 613-628.	13.5	1,957
96	Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. <i>Clinical Cancer Research</i> , 2017, 23, 4716-4723.	3.2	102
97	Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 948-955.	1.9	81
98	Patient monitoring through liquid biopsies using circulating tumor DNA. <i>International Journal of Cancer</i> , 2017, 141, 887-896.	2.3	46
99	Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). <i>Targeted Oncology</i> , 2017, 12, 513-523.	1.7	21
100	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	1.2	34
101	Analytic and Clinical Validation of an Ultrasensitive, Quantitative Polymerase Chain Reaction Assay for EGFR Mutation Analysis With Circulating Tumor DNA. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 978-984.	1.2	9
102	AACR Project GENIE: Powering Precision Medicine through an International Consortium. <i>Cancer Discovery</i> , 2017, 7, 818-831.	7.7	1,235
103	Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance. <i>Oncology Letters</i> , 2017, 13, 4549-4557.	0.8	21
104	New insights into the role of <sc>EMT</sc> in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
105	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017, 77, 1510-1541.	0.4	116
107	Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 375-384.	1.6	12
108	Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. <i>Cancer Medicine</i> , 2017, 6, 962-974.	1.3	27
109	Emerging concepts in liquid biopsies. <i>BMC Medicine</i> , 2017, 15, 75.	2.3	211
110	CTCs and ctDNA: Two Tales of a Complex Biology. <i>Cancer Drug Discovery and Development</i> , 2017, , 119-137.	0.2	1

#	ARTICLE	IF	CITATIONS
111	Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers. <i>International Journal of Cancer</i> , 2017, 140, 1436-1446.	2.3	37
112	Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 663-672.	0.5	100
113	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
114	Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection. <i>Npj Genomic Medicine</i> , 2017, 2, 34.	1.7	42
115	The potential of liquid biopsies for the early detection of cancer. <i>Npj Precision Oncology</i> , 2017, 1, 36.	2.3	126
116	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , 2017, 8, 1093.	5.8	515
117	Integrating multiple fitting regression and Bayes decision for cancer diagnosis with transcriptomic data from tumor-educated blood platelets. <i>Analyst</i> , The, 2017, 142, 3588-3597.	1.7	8
118	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. <i>Cancer Genetics</i> , 2017, 218-219, 39-50.	0.2	42
119	The diagnostic potential of mutation detection from single circulating tumor cells in cancer patients. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 975-981.	1.5	11
120	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
121	Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. <i>Cancer Research</i> , 2017, 77, 5194-5206.	0.4	139
122	Cell-free ctDNA: Minimally invasive marker of hematological malignancies. <i>European Journal of Haematology</i> , 2017, 99, 291-299.	1.1	28
123	Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells. <i>Cellular and Molecular Bioengineering</i> , 2017, 10, 275-294.	1.0	34
124	Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor- $\beta$ receptor I in head and neck cancer. <i>Head and Neck</i> , 2017, 39, 2283-2292.	0.9	28
125	Technologies for analysis of circulating tumour DNA: Progress and promise. <i>TrAC - Trends in Analytical Chemistry</i> , 2017, 97, 36-49.	5.8	20
126	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	808
127	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2017, 23, 2471-2477.	3.2	154
128	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 60-67.	1.1	6



#	ARTICLE	IF	CITATIONS
129	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 13-27.	1.5	38
130	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 52, 33-40.	3.4	75
131	Detection of somatic variants and <i>EGFR</i> mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction. <i>Oncotarget</i> , 2017, 8, 106901-106912.	0.8	20
132	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369.	1.8	9
133	Circulating Tumor Cells: Moving Biological Insights into Detection. <i>Theranostics</i> , 2017, 7, 2606-2619.	4.6	104
134	Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4527-4534.	1.0	55
135	Liquid Biopsies for Cancer: Coming to a Patient near You. <i>Journal of Clinical Medicine</i> , 2017, 6, 3.	1.0	75
136	Peptide Nucleic Acid-Based Biosensors for Cancer Diagnosis. <i>Molecules</i> , 2017, 22, 1951.	1.7	83
137	Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers. <i>Sensors</i> , 2017, 17, 2934.	2.1	60
138	Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 26.	1.3	79
139	Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. <i>Disease Markers</i> , 2017, 2017, 1-11.	0.6	13
140	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	39
141	Predicting cancer type from tumour DNA signatures. <i>Genome Medicine</i> , 2017, 9, 104.	3.6	40
142	Evaluating somatic tumor mutation detection without matched normal samples. <i>Human Genomics</i> , 2017, 11, 22.	1.4	42
143	Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva. <i>The Enzymes</i> , 2017, 42, 125-151.	0.7	82
144	Circulating tumor cells: silent predictors of metastasis. <i>F1000Research</i> , 2017, 6, 1445.	0.8	37
145	The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1090-1110.	0.6	22
146	Emerging role of liquid biopsy of cell-free tumor DNA for bladder cancer surveillance. <i>Translational Andrology and Urology</i> , 2017, 6, 590-592.	0.6	0

#	ARTICLE	IF	CITATIONS
147	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018, 28, 195-203.	0.6	17
148	Liquid Biopsy in Head and Neck Cancer: Promises and Challenges. <i>Journal of Dental Research</i> , 2018, 97, 701-708.	2.5	92
149	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	7.7	157
150	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	5.1	108
151	Methylation in cell-free DNA for early cancer detection. <i>Annals of Oncology</i> , 2018, 29, 1351-1353.	0.6	22
152	Three-dimensional microfluidic chip with twin-layer herringbone structure for high efficient tumor cell capture and release via antibody-conjugated magnetic microbeads. <i>Electrophoresis</i> , 2018, 39, 1452-1459.	1.3	17
153	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2018, 29, i10-i19.	0.6	449
154	Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. <i>British Journal of Surgery</i> , 2018, 105, e110-e120.	0.1	49
155	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
156	Molecular pathology of lung cancer: current status and perspectives. <i>Current Opinion in Oncology</i> , 2018, 30, 69-76.	1.1	82
157	Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 10-11.	0.5	4
158	The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis. <i>Current Problems in Cancer</i> , 2018, 42, 95-106.	1.0	50
159	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. <i>Advanced Drug Delivery Reviews</i> , 2018, 125, 122-131.	6.6	21
160	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 329-340.	3.0	76
161	Exosomes: Definition, Role in Tumor Development and Clinical Implications. <i>Cancer Microenvironment</i> , 2018, 11, 13-21.	3.1	39
162	Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA. <i>Methods in Molecular Biology</i> , 2018, 1768, 303-322.	0.4	3
163	The Molecular Communications Markup Language (MolComML). <i>Nano Communication Networks</i> , 2018, 16, 12-25.	1.6	4
164	Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. <i>Lab on A Chip</i> , 2018, 18, 1174-1196.	3.1	234

#	ARTICLE	IF	CITATIONS
165	Screening for ovarian cancer: imaging challenges and opportunities for improvement. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 293-303.	0.9	69
166	Capturing Circulating Tumor Cells through a Combination of Hierarchical Nanotopography and Surface Chemistry. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 2081-2088.	2.6	12
167	Monitoring resistance through liquid biopsy. <i>Annals of Oncology</i> , 2018, 29, 8-11.	0.6	52
168	Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2018, 12, 48-57.	2.1	52
169	Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 117-140.	9.6	97
170	Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. <i>Oncologist</i> , 2018, 23, 121-127.	1.9	21
171	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 560-568.	3.2	120
172	Emerging data on improving response to hormone therapy: the role of novel targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 3-18.	1.1	2
173	Specific capture, recovery and culture of cancer cells using oriented antibody-modified polystyrene chips coated with agarose film. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 162, 306-315.	2.5	8
174	Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 964-977.	1.8	19
175	Liquid biopsy for lung cancer early detection. <i>Journal of Thoracic Disease</i> , 2018, 10, S882-S897.	0.6	93
176	Expanding the gamut of circulating tumor DNA applications. <i>Journal of Thoracic Disease</i> , 2018, 10, S4151-S4155.	0.6	0
177	Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis. <i>Medicine (United States)</i> , 2018, 97, e11346.	0.4	13
178	Developing a Roadmap for Interventional Oncology. <i>Oncologist</i> , 2018, 23, 1162-1170.	1.9	19
179	Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond. <i>Lab on A Chip</i> , 2018, 19, 11-34.	3.1	123
180	Liquid Biopsy for Colorectal Cancer Screening, A Modern Approach for Patients Stratification and Monitoring. , 2018, , .		0
181	Circulating tumor DNA detection: A potential tool for colorectal cancer management (Review). <i>Oncology Letters</i> , 2019, 17, 1409-1416.	0.8	38
182	Interdigitated Micro Electrode Array Dielectrophoretic System for Label-free Multi-Parameter-based Cell Detection. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
183	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. <i>Cancer Genetics</i> , 2018, 228-229, 131-142.	0.2	5
184	Microfluidics for minute DNA sample analysis: open challenges for genetic testing of cell-free circulating DNA in blood plasma. <i>Micro and Nano Engineering</i> , 2018, 1, 25-32.	1.4	8
185	The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 610.	1.3	6
186	Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1213-1219.	1.1	60
187	What Is the Future of Circulating Tumor Cells in Colorectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 207-216.	1.0	0
188	Effective reduction of non-specific binding of blood cells in a microfluidic chip for isolation of rare cancer cells. <i>Biomaterials Science</i> , 2018, 6, 2871-2880.	2.6	15
189	Novel molecular insights and new therapeutic strategies in osteosarcoma. <i>Cancer Cell International</i> , 2018, 18, 158.	1.8	73
190	Automated DNA extraction using cellulose magnetic beads can improve EGFR point mutation detection with liquid biopsy by efficiently recovering short and long DNA fragments. <i>Oncotarget</i> , 2018, 9, 25181-25192.	0.8	27
191	Application of Cell-free DNA Analysis to Cancer Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 1754-1765.	13.9	634
192	Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3356.	1.8	79
193	Role of liquid biopsies in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 593-600.	1.0	22
194	A versatile label-free electrochemical biosensor for circulating tumor DNA based on dual enzyme assisted multiple amplification strategy. <i>Biosensors and Bioelectronics</i> , 2018, 122, 224-230.	5.3	70
195	Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. <i>World Journal of Gastroenterology</i> , 2018, 24, 2236-2246.	1.4	38
196	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434
197	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1626-1635.	1.5	46
198	Clinical value of circulating <em>ESR1</em> mutations for patients with metastatic breast cancer: a meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 2573-2580.	0.9	32
199	An algorithm to evaluate the efficacy of detecting somatic mutations. <i>Journal of Solid Tumors</i> , 2018, 8, 25.	0.1	0
200	Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma. <i>Clinical Cancer Research</i> , 2018, 24, 5724-5734.	3.2	43

#	ARTICLE	IF	CITATIONS
201	Exosomes, Stem Cells and MicroRNA. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	1
202	Advancements in microfluidic technologies for isolation and early detection of circulating cancer-related biomarkers. <i>Analyst, The</i> , 2018, 143, 2971-2991.	1.7	39
203	HPV â€œ Das andere Kopf-Hals-Karzinom. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S48-S113.	0.2	35
204	Identification of circulating tumor cells with EML4â€™ALK translocation using fluorescence in-situ hybridization in advanced ALKâ€™positive patients with lung cancer. <i>Oncology Letters</i> , 2018, 15, 8959-8964.	0.8	3
205	Microfluidic technologies for circulating tumor cell isolation. <i>Analyst, The</i> , 2018, 143, 2936-2970.	1.7	130
206	Liquid Biopsy in Tumor Genetic Diagnosis. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2018, 115, 169-174.	0.6	32
207	Circulating tumor DNA in blood: Future genomic biomarkers for cancer detection. <i>Experimental Hematology</i> , 2018, 65, 17-28.	0.2	30
208	Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. <i>Current Oncology</i> , 2018, 25, 73-82.	0.9	24
209	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	2.8	118
210	Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells â€™ is a new era coming?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 376-407.	2.7	16
211	Improving Cancer Detection and Treatment with Liquid Biopsies and ctDNA. <i>Trends in Cancer</i> , 2018, 4, 643-654.	3.8	6
212	From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity. <i>Frontiers in Pharmacology</i> , 2018, 9, 77.	1.6	21
213	The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies. <i>Frontiers in Oncology</i> , 2018, 8, 263.	1.3	7
214	Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 57, 268-275.	1.4	14
215	The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring. <i>Current Oncology Reports</i> , 2018, 20, 70.	1.8	58
216	EV, Microvesicles/MicroRNAs and Stem Cells in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1056, 123-135.	0.8	5
217	Blood-based biomarkers for the diagnosis and monitoring of gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1155-1161.	0.6	67
218	Evaluation of pre-analytical factors affecting plasma DNA analysis. <i>Scientific Reports</i> , 2018, 8, 7375.	1.6	102

#	ARTICLE	IF	CITATIONS
219	Pancreatic cancer circulating tumor cells: applications for personalized oncology. Expert Review of Molecular Diagnostics, 2018, 18, 809-820.	1.5	26
220	LncRNAs and <em>EGFRvIII</em> sequestered in TEPs enable blood-based NSCLC diagnosis. Cancer Management and Research, 2018, Volume 10, 1449-1459.	0.9	38
221	The dawn of the liquid biopsy in the fight against cancer. Oncotarget, 2018, 9, 2912-2922.	0.8	93
222	Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget, 2018, 9, 26900-26933.	0.8	47
223	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Seminars in Liver Disease, 2018, 38, 160-169.	1.8	50
224	Molecular Assessment of Human Diseases in the Clinical Laboratory. , 2018, , 709-730.		2
225	Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?. Biomarkers in Cancer, 2018, 10, 1179299X1877697.	3.6	4
226	Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes. Clinical and Translational Oncology, 2019, 21, 342-347.	1.2	15
227	Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1501-1510.	1.4	20
228	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clinical Cancer Research, 2019, 25, 6107-6118.	3.2	54
229	Towards the Delivery of Precision Veterinary Cancer Medicine. Veterinary Clinics of North America - Small Animal Practice, 2019, 49, 809-818.	0.5	12
231	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18.	2.3	25
232	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Current Hematologic Malignancy Reports, 2019, 14, 358-367.	1.2	13
233	Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncology, 2019, 95, 120-126.	0.8	33
234	CALDER: Inferring Phylogenetic Trees from Longitudinal Tumor Samples. Cell Systems, 2019, 8, 514-522.e5.	2.9	46
235	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. Cells, 2019, 8, 1251.	1.8	53
236	Isolation and Retrieval of Extracellular Vesicles for Liquid Biopsy of Malignant Ground-Glass Opacity. Analytical Chemistry, 2019, 91, 13729-13736.	3.2	21
237	Cytomorphological Characterization of Individual Metastatic Tumor Cells from Gastrointestinal Cancer Patient Lymph Nodes with Imaging Flow Cytometry. Gastrointestinal Disorders, 2019, 1, 372-384.	0.4	0

#	ARTICLE	IF	CITATIONS
238	Liquid Biopsy in Oligometastatic Prostate Cancer—A Biologist's Point of View. <i>Frontiers in Oncology</i> , 2019, 9, 775.	1.3	21
239	Towards Circulating-Tumor DNA-Based Precision Medicine. <i>Journal of Clinical Medicine</i> , 2019, 8, 1365.	1.0	8
240	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	15.2	359
241	Multilayer microfluidic array for highly efficient sample loading and digital melt analysis of DNA methylation. <i>Lab on A Chip</i> , 2019, 19, 444-451.	3.1	20
242	Microfluidic device for circulating tumor cell quantification and capture. <i>AIP Conference Proceedings</i> , 2019, , .	0.3	0
243	Liquid biopsy in breast cancer: A comprehensive review. <i>Clinical Genetics</i> , 2019, 95, 643-660.	1.0	210
244	Role of Saliva and Salivary Diagnostics in the Advancement of Oral Health. <i>Journal of Dental Research</i> , 2019, 98, 133-141.	2.5	116
245	Rapid prototyping of Nanoroughened polydimethylsiloxane surfaces for the enhancement of immunomagnetic isolation and recovery of rare tumor cells. <i>Biomedical Microdevices</i> , 2019, 21, 58.	1.4	6
246	Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. <i>Cells</i> , 2019, 8, 618.	1.8	14
247	Surface-Enhanced Raman Spectroscopy in Cancer Diagnosis, Prognosis and Monitoring. <i>Cancers</i> , 2019, 11, 748.	1.7	71
248	Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 108-116.	0.9	22
249	Combined effects of fluid type and particle shape on particles flow in microfluidic platforms. <i>Microfluidics and Nanofluidics</i> , 2019, 23, 1.	1.0	10
250	Acoustofluidic separation of cells and particles. <i>Microsystems and Nanoengineering</i> , 2019, 5, 32.	3.4	268
251	EGFR point mutation detection of single circulating tumor cells for lung cancer using a micro-well array. <i>Biosensors and Bioelectronics</i> , 2019, 139, 111326.	5.3	19
252	Serum Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 107-117.	0.0	0
253	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
254	Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. <i>Journal of Clinical Medicine</i> , 2019, 8, 373.	1.0	107
255	Recent Advances in Liquid Biopsy in Precision Oncology Research. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 337-342.	0.6	27



#	ARTICLE	IF	CITATIONS
256	Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. EBioMedicine, 2019, 41, 345-356.	2.7	59
257	Liquid biopsy for cancer diagnosis and screening – The promise and challenges. Annals of Clinical Biochemistry, 2019, 56, 420-423.	0.8	1
258	Conventional and Novel Diagnostic Biomarkers and Approaches for Detection of Nasopharyngeal Carcinoma. , 2019, , 129-153.		1
259	Leukocyte-Repelling Biomimetic Immunomagnetic Nanoplatform for High-Performance Circulating Tumor Cells Isolation. Small, 2019, 15, e1900558.	5.2	48
260	Oncosuppressor-Mutated Cells as a Liquid Biopsy Test for Cancer-Screening. Scientific Reports, 2019, 9, 2384.	1.6	9
261	Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nature Biomedical Engineering, 2019, 3, 438-451.	11.6	382
262	Computational Intelligence Methods for Bioinformatics and Biostatistics. Lecture Notes in Computer Science, 2019, , .	1.0	0
263	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. Cancers, 2019, 11, 238.	1.7	26
264	Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. Acta Cytologica, 2019, 63, 171-181.	0.7	5
265	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precision Oncology, 2019, 3, 1-10.	1.5	6
266	Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS ONE, 2019, 14, e0227366.	1.1	57
267	Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019. BioMed Research International, 2019, 2019, 1-11.	0.9	12
268	High sensitive detection of circulating tumor cell by multimer lipid magnetic nanoparticles and clinical verifications. Journal of Nanobiotechnology, 2019, 17, 116.	4.2	21
269	Ovarian cancer detection by DNA methylation in cervical scrapings. Clinical Epigenetics, 2019, 11, 166.	1.8	22
270	The Gasdermin E gene Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types. Cancers, 2019, 11, 1810.	1.7	24
271	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	1.7	27
272	Current Utility and Future Applications of ctDNA in Colorectal Cancer. , 0, , .		0
273	Advanced liquid biopsy technologies for circulating biomarker detection. Journal of Materials Chemistry B, 2019, 7, 6670-6704.	2.9	118



#	ARTICLE	IF	CITATIONS
274	Sixâ€Gene Assay as a new biomarker in the blood of patients with colorectal cancer: establishment and clinical validation. <i>Molecular Oncology</i> , 2019, 13, 781-791.	2.1	13
275	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. <i>European Journal of Cancer</i> , 2019, 106, 133-143.	1.3	35
276	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213.	0.4	75
277	Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 195-205.	2.0	39
278	Prognostic and Predictive Role of Circulating Tumor Cells. , 2019, , 181-190.		1
279	The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a036269.	2.9	43
280	A plasma metabolite panel as biomarkers for early primary breast cancer detection. <i>International Journal of Cancer</i> , 2019, 144, 2833-2842.	2.3	50
281	Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment. <i>Oncology</i> , 2019, 96, 115-124.	0.9	11
282	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. <i>Clinical Chemistry</i> , 2019, 65, 559-568.	1.5	17
283	Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. <i>Cancers</i> , 2019, 11, 58.	1.7	22
284	Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. <i>Cancers</i> , 2019, 11, 59.	1.7	47
285	Characterizing Circulating Tumor Cells Isolated from Metastatic Breast Cancer Patients Using Graphene Oxide Based Microfluidic Assay. <i>Advanced Biology</i> , 2019, 3, e1800278.	3.0	19
286	KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 375-385.	1.1	22
287	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 1494-1504.	3.2	45
288	Exploring the Fundamental Structures of Life: Nonâ€Targeted, Chemical Analysis of Single Cells and Subcellular Structures. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 9348-9364.	7.2	65
289	Erforschung der fundamentalen Strukturen des Lebens: Nicht zielgerichtete chemische Analyse von Einzelzellen und subzellulären Strukturen. <i>Angewandte Chemie</i> , 2019, 131, 9448-9465.	1.6	5
290	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
291	Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 56-63.	0.9	20

#	ARTICLE	IF	CITATIONS
292	Liquid Biopsy Applications in the Clinic. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 125-132.	1.6	33
293	Microfluidic systems for cancer diagnostics. <i>Current Opinion in Biotechnology</i> , 2020, 65, 37-44.	3.3	71
294	The evolution of molecular diagnosis using digital polymerase chain reaction to detect cancer via cell-free DNA and circulating tumor cells. <i>Cell Biology International</i> , 2020, 44, 735-743.	1.4	7
295	The microcosmos of intratumor heterogeneity: the space-time of cancer evolution. <i>Oncogene</i> , 2020, 39, 2031-2039.	2.6	48
296	Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. <i>Anti-Cancer Drugs</i> , 2020, 31, 979-982.	0.7	6
297	Non-invasive detection of EGFR mutations by cell-free loop-mediated isothermal amplification (CF-LAMP). <i>Scientific Reports</i> , 2020, 10, 17559.	1.6	5
298	Nondestructive capture, release, and detection of circulating tumor cells with cystamine-mediated folic acid decorated magnetic nanospheres. <i>Journal of Materials Chemistry B</i> , 2020, 8, 9971-9979.	2.9	20
299	Recent advances in microfluidic technologies for circulating tumor cells: enrichment, single-cell analysis, and liquid biopsy for clinical applications. <i>Lab on A Chip</i> , 2020, 20, 3854-3875.	3.1	63
300	Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200.	0.8	24
301	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. <i>Cancers</i> , 2020, 12, 1831.	1.7	29
302	Cytoplasm protein GFAP magnetic beads construction and application as cell separation target for brain tumors. <i>Journal of Nanobiotechnology</i> , 2020, 18, 169.	4.2	10
303	Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1213-1227.	1.5	17
304	Uniform palladium nanosheets for fluorimetric detection of circulating tumor DNA. <i>Analytica Chimica Acta</i> , 2020, 1139, 164-168.	2.6	17
305	Advanced pneumonic type of lung adenocarcinoma: survival predictors and treatment efficacy of the tumor. <i>Tumori</i> , 2020, 107, 030089162094715.	0.6	4
306	Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer. <i>Diagnostics</i> , 2020, 10, 523.	1.3	2
307	Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. <i>Pharmaceuticals</i> , 2020, 13, 180.	1.7	31
308	Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , .	0.2	1
309	Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC. <i>Advanced Biology</i> , 2020, 4, e2000110.	3.0	12

#	ARTICLE	IF	CITATIONS
310	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	1.7	49
311	Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1340-1346.	1.2	10
312	Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 18682.	1.6	40
313	Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 441-452.	1.0	78
314	Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood. <i>Current Treatment Options in Oncology</i> , 2020, 21, 89.	1.3	2
315	Microfluidics for label-free sorting of rare circulating tumor cells. <i>Analyst</i> , 2020, 145, 7103-7124.	1.7	57
316	A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1507-1515.	1.3	6
317	Chasing ctDNA in Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e351-e360.	1.8	8
318	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1084.	1.7	17
319	A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC. <i>Theranostics</i> , 2020, 10, 5181-5194.	4.6	17
320	Clinical Application of Mass Spectrometry-Based Proteomics in Lung Cancer Early Diagnosis. <i>Proteomics - Clinical Applications</i> , 2020, 14, 1900138.	0.8	14
322	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 114-125.	2.9	14
323	Characterization of a novel automated microfiltration device for the efficient isolation and analysis of circulating tumor cells from clinical blood samples. <i>Scientific Reports</i> , 2020, 10, 7543.	1.6	9
324	Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 1352.	1.7	13
325	Circulating tumour cells as prognosis predictive markers of neoadjuvant chemotherapy-treated breast cancer patients. <i>Journal of Chemotherapy</i> , 2020, 32, 304-309.	0.7	4
326	The potential of liquid biopsies in gastrointestinal cancer. <i>Clinical Biochemistry</i> , 2020, 84, 1-12.	0.8	14
327	Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 665-677.	1.1	1
328	Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?. <i>Medical Oncology</i> , 2020, 37, 29.	1.2	34

#	ARTICLE	IF	CITATIONS
329	Liquid biopsies for early cancer detection. , 2020, , 233-259.		5
330	Targeting Circulating SINEs and LINEs with DNase I Provides Metastases Inhibition in Experimental Tumor Models. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 50-61.	2.3	20
331	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. <i>European Radiology</i> , 2020, 30, 4496-4503.	2.3	7
332	&lt;p&gt;Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 719-731.	1.0	11
333	Gold Nanoparticles-based Bio-Sensing Methods for Tumor-related Biomedical Applications in Bodily Fluids. <i>Current Nanoscience</i> , 2020, 16, 425-440.	0.7	2
334	Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer. <i>Sensors</i> , 2020, 20, 1317.	2.1	40
335	Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection. <i>Scientific Reports</i> , 2020, 10, 4124.	1.6	23
336	Upconversion nanoparticle and gold nanocage satellite assemblies for sensitive ctDNA detection in serum. <i>Analyst, The</i> , 2020, 145, 5553-5562.	1.7	22
337	Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care. <i>Cancers</i> , 2020, 12, 1710.	1.7	24
338	Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. <i>Genome Biology</i> , 2020, 21, 162.	3.8	14
339	Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. <i>Cells</i> , 2020, 9, 1594.	1.8	9
340	Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16839-16847.	3.3	101
341	Emerging Techniques in Imaging of Glioma Microenvironment. <i>Topics in Magnetic Resonance Imaging</i> , 2020, 29, 103-114.	0.7	4
342	A comparative study on EpCAM antibody immobilization on gold surfaces and microfluidic channels for the detection of circulating tumor cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 188, 110808.	2.5	17
343	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020, 11, 525.	5.8	158
344	â€œSample-to-Answerâ€•Detection of Rare ctDNA Mutation from 2 mL Plasma with a Fully Integrated DNA Extraction and Digital Droplet PCR Microdevice for Liquid Biopsy. <i>Analytical Chemistry</i> , 2020, 92, 7240-7248.	3.2	37
345	Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges. <i>Pharmacogenomics</i> , 2020, 21, 359-367.	0.6	8
346	Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. <i>Annals of Hematology</i> , 2020, 99, 1293-1302.	0.8	15

#	ARTICLE	IF	CITATIONS
347	A novel device to capture circulating tumor cells: Quantification and molecular analysis in lung cancer patients. <i>Journal of Biomaterials Applications</i> , 2020, 35, 49-58.	1.2	2
348	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240.	2.9	34
349	Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 284-294.	1.1	12
350	A label-free microfluidic chip for the highly selective isolation of single and cluster CTCs from breast cancer patients. <i>Translational Oncology</i> , 2021, 14, 100959.	1.7	16
351	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103188.	2.0	17
352	When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e35-e39.	0.7	3
353	The Present and Future of Screening in Breast Cancer Prevention. , 2021, , 163-173.		0
354	Dynamic Changes of Fetal-Derived Hypermethylated RASSF1A and Septin 9 Sequences in Maternal Plasma. <i>Reproductive Sciences</i> , 2021, 28, 1194-1199.	1.1	3
355	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. <i>Cancers</i> , 2021, 13, 451.	1.7	24
356	Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy. <i>Journal of Materials Chemistry B</i> , 2021, 9, 2946-2978.	2.9	8
357	A homogeneous digital biosensor for circulating tumor DNA by the enumeration of a dual-color quantum dot complex. <i>Analyst</i> , The, 2021, 146, 3034-3040.	1.7	3
358	DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 622579.	1.8	20
359	Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 337-361.	0.8	6
361	Circulating free DNA in the plasma of individuals with neurofibromatosis type 1. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 1098-1104.	0.7	4
362	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
363	Circulating Biomarkers in Head and Neck Cancer. , 2021, , 123-142.		0
364	Nanopore Identification of Single Nucleotide Mutations in Circulating Tumor DNA by Multiplexed Ligation. <i>Clinical Chemistry</i> , 2021, 67, 753-762.	1.5	20
365	Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. <i>Oncotarget</i> , 2021, 12, 63-65.	0.8	1

#	ARTICLE	IF	CITATIONS
366	Cell-Free DNA: Hope and Potential Application in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 639233.	1.8	60
367	Human TERT promoter mutations as a prognostic biomarker in glioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1007-1017.	1.2	21
368	Advanced nanomaterials as sample technique for bio-analysis. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 135, 116168.	5.8	70
369	Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution. <i>Cancers</i> , 2021, 13, 1380.	1.7	38
370	Could Extracellular Vesicles Contribute to Generation or Awakening of "Sleepy" Metastatic Niches?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 625221.	1.8	11
371	Advances in single-molecule fluorescent nanosensors. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1716.	3.3	19
373	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 "Radiological features and metric markers. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103230.	2.0	32
375	Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1256-1265.	1.3	9
376	Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 315-325.	1.0	5
377	When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. <i>Oncology and Therapy</i> , 2021, 9, 89-110.	1.0	36
378	Silver-coated silicon nanowire platform discriminates genomic DNA from normal and malignant human epithelial cells using label-free Raman spectroscopy. <i>Materials Science and Engineering C</i> , 2021, 122, 111951.	3.8	10
379	Inertial Microfluidics Enabling Clinical Research. <i>Micromachines</i> , 2021, 12, 257.	1.4	29
380	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. <i>Lung Cancer</i> , 2021, 154, 161-175.	0.9	105
381	Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level. <i>Cancer Science</i> , 2021, 112, 2006-2019.	1.7	7
382	Differential Mutation Detection Capability Through Capture-Based Targeted Sequencing in Plasma Samples in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 596789.	1.3	8
383	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. <i>Seminars in Cancer Biology</i> , 2022, 84, 199-213.	4.3	35
384	Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation. <i>Cancers</i> , 2021, 13, 2101.	1.7	14
385	Current status of ctDNA in precision oncology for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 140.	3.5	15

#	ARTICLE	IF	CITATIONS
386	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021, 13, 1861.	1.7	4
387	Herringbone Microfluidic Probe for Multiplexed Affinityâ€Capture of Prostate Circulating Tumor Cells. <i>Advanced Materials Technologies</i> , 2021, 6, 2100053.	3.0	17
388	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609.	0.3	0
389	Applications of Microfluidic Devices in the Diagnosis and Treatment of Cancer: A Review Study. <i>Critical Reviews in Analytical Chemistry</i> , 2022, 52, 1863-1877.	1.8	14
390	KRAS G12Câ€Mutant Nonâ€Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 507-520.	1.2	40
391	Molecular approaches to lung cancer prevention. <i>Future Oncology</i> , 2021, 17, 1793-1810.	1.1	3
392	Identification of mutant K-RAS in pituitary macroadenoma. <i>Pituitary</i> , 2021, 24, 746-753.	1.6	6
393	A DNA methylation-based liquid biopsy for triple-negative breast cancer. <i>Npj Precision Oncology</i> , 2021, 5, 53.	2.3	11
394	Lung Cancer Stem Cellsâ€Origin, Diagnostic Techniques and Perspective for Therapies. <i>Cancers</i> , 2021, 13, 2996.	1.7	14
395	Machine Learning Protocols in Early Cancer Detection Based on Liquid Biopsy: A Survey. <i>Life</i> , 2021, 11, 638.	1.1	28
396	In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies. <i>Journal of Controlled Release</i> , 2021, 334, 164-177.	4.8	19
397	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021, 26, 865-878.	1.9	39
398	Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer. , 0, , .		0
399	Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities. <i>Oncogene</i> , 2021, 40, 5204-5212.	2.6	21
400	Development of Imaging and Liquid Biomarker Analysis for Breast Cancer Screening: A Review. <i>Pharmaceutical Sciences</i> , 2021, , .	0.1	1
401	Photoelectrochemical assay for the detection of circulating tumor cells based on aptamer-Ag2S nanocrystals for signal amplification. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5259-5266.	1.9	11
402	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, e1812-e1821.	1.9	15
403	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 4055.	1.7	1



#	ARTICLE	IF	CITATIONS
404	Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response. <i>Frontiers in Genetics</i> , 2021, 12, 734595.	1.1	24
405	Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing. <i>Cancers</i> , 2021, 13, 4190.	1.7	3
406	Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4209.	1.7	6
407	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021, 17, 4607-4618.	1.1	4
408	Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. <i>Frontiers in Oncology</i> , 2021, 11, 666340.	1.3	5
409	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. <i>Scientific Reports</i> , 2021, 11, 16333.	1.6	14
410	Highly sensitive fusion detection using plasma cell-free RNA in non-small cell lung cancers. <i>Cancer Science</i> , 2021, 112, 4393-4403.	1.7	21
411	The scope of liquid biopsy in the clinical management of oral cancer. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2022, 51, 591-601.	0.7	11
412	Liquid biopsy: the current state of the issue. <i>Innovative Medicine of Kuban</i> , 2021, , 57-63.	0.0	1
413	Circulating Biomarkers in Glioblastoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 404-409.	1.0	4
414	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021, 13, 4743.	1.7	8
415	Application of lanthanide-doped upconversion nanoparticles for cancer treatment: a review. <i>Nanomedicine</i> , 2021, 16, 2207-2242.	1.7	15
416	Circulating Tumor DNA Harboring the <i>BRAF</i> <sup>V600E</sup> Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients. <i>Thyroid</i> , 2021, 31, 1822-1828.	2.4	6
417	Detection of Circulating Tumor Cells Using Three-dimensional and Conditionally Reprogrammed Culture Methods. <i>Laboratory Medicine Online</i> , 2021, 11, 297-304.	0.0	0
418	PhosphoFlowSeq – A High-throughput Kinase Activity Assay for Screening Drug Resistance Mutations in EGFR. <i>Journal of Molecular Biology</i> , 2021, 433, 167210.	2.0	3
419	Photonic crystal barcode: An emerging tool for cancer diagnosis. <i>Smart Materials in Medicine</i> , 2021, 2, 182-195.	3.7	5
420	Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12% 139 Cancer Patients. <i>Clinical Chemistry</i> , 2021, 67, 1554-1566.	1.5	13
421	Microtechnology-enabled filtration-based liquid biopsy: challenges and practical considerations. <i>Lab on A Chip</i> , 2021, 21, 994-1015.	3.1	10



#	ARTICLE	IF	CITATIONS
423	Enrichment and Analysis of ctDNA. Recent Results in Cancer Research, 2020, 215, 181-211.	1.8	13
424	Circulating Tumor Cells in Gastrointestinal Cancer: Current Practices and Future Directions. Cancer Treatment and Research, 2016, 168, 345-376.	0.2	8
425	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Cancer Treatment Reviews, 2020, 87, 102028.	3.4	9
429	Sensitive and easy screening for circulating tumor cells by flow cytometry. JCI Insight, 2019, 4, .	2.3	31
430	An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. JCI Insight, 2016, 1, .	2.3	16
431	Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. Journal of Clinical Investigation, 2019, 129, 2463-2479.	3.9	4
432	Estimating Exceptionally Rare Germline and Somatic Mutation Frequencies via Next Generation Sequencing. PLoS ONE, 2016, 11, e0158340.	1.1	12
433	Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. PLoS ONE, 2020, 15, e0239819.	1.1	46
434	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	8
435	Gene expression-based clinical predictions in lung adenocarcinoma. Aging, 2020, 12, 15492-15503.	1.4	4
436	Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. Oncotarget, 2017, 8, 2771-2780.	0.8	68
437	Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 97769-97786.	0.8	28
438	Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. Oncotarget, 2018, 9, 31904-31914.	0.8	25
439	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. Oncotarget, 2019, 10, 6494-6508.	0.8	19
440	Enhanced detection and comprehensive <i>in situ</i> phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells. Oncotarget, 2015, 6, 27049-27064.	0.8	52
441	Extracellular RNAs as potential biomarkers for cancer. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.5	15
442	Evolving insights: how DNA repair pathways impact cancer evolution. Cancer Biology and Medicine, 2020, 17, 805-827.	1.4	17
443	Detection of circulating stage III-IV gastric cancer tumor cells based on isolation by size of epithelial tumor: using the circulating tumor cell biopsy technology. Translational Cancer Research, 2019, 8, 1342-1350.	0.4	6

#	ARTICLE	IF	CITATIONS
444	A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 135-143.	1.3	12
445	Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 579-588.	0.7	22
446	Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 112-122.	0.9	14
447	EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. <i>Anticancer Research</i> , 2017, 37, 2721-2725.	0.5	9
448	Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening. <i>Iranian Biomedical Journal</i> , 2018, 22, 331-337.	0.4	10
449	Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1290.	1.8	10
450	Recent advances in surface-enhanced Raman spectroscopy based liquid biopsy for colorectal cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	10
451	<i>KRAS</i> and <i>NRAS</i> mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation. <i>Oncology Letters</i> , 2020, 21, 15.	0.8	8
452	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. <i>Translational Lung Cancer Research</i> , 2015, 4, 126-41.	1.3	59
453	DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 533.	0.8	18
454	Liquid biopsy using extracellular vesicle-derived DNA in lung adenocarcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 453-461.	0.4	16
455	Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic <i>PIK3CA</i> or <i>KRAS</i> Mutations. <i>Cancer Research and Treatment</i> , 2020, 52, 1219-1228.	1.3	9
456	Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. <i>Cancer Biology and Therapy</i> , 2021, 22, 564-570.	1.5	7
457	Medical Approach to Wellness. , 2015, , 1-12.		0
458	Medical Approach to Wellness. , 2016, , 861-875.		0
459	Abstract A40: Protein disulfide isomerases in the endoplasmic reticulum promote anchorage-independent growth of breast cancer cells. , 2016, , .		0
461	Detection of the <i>PIK3CA</i> Mutation in Circulating Tumor DNA as a Possible Predictive Indicator for Poor Prognosis of Early-Stage Breast Cancer. <i>Journal of Cancer Therapy</i> , 2018, 09, 42-54.	0.1	2
464	A Nano Communication System for CTC Detection in Blood Vessels. <i>Lecture Notes in Computer Science</i> , 2019, , 159-170.	1.0	0

#	ARTICLE	IF	CITATIONS
465	Liquid biopsy—Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis. <i>Oral Oncology</i> , 2021, 123, 105588.	0.8	12
466	Overview of Early Detection of Gastrointestinal Cancer. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 117-129.	0.2	2
467	Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets. <i>Oncology &amp; Hematology Review</i> , 2020, 16, 36.	0.2	0
470	La biopsia líquida en el diagnóstico y monitoreo de pacientes oncológicos: oportunidades y retos en Latinoamérica. <i>Revista Colombiana De Cancerología</i> , 2020, 24, 164-77.	0.0	1
471	Liquid Biopsy in the OMICS Era of Tumor Medicine. , 2018, 1, .		1
475	Epigenetic biomarker and drug development in gynecological cancers. , 2022, , 223-255.		0
477	Impact of epidermal growth factor receptor T790M testing in relapsed non-small cell lung cancer: A narrative review of the T790M reflex testing algorithm. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 692.	0.1	3
478	Folyadokbiopszia-vizsgálatok alkalmazási lehetőségei az onkohematológiában. <i>Transfusio</i> , 2020, 53, 144-156.	0.0	1
479	The Role of Small Extracellular Vesicles in the Progression of Colorectal Cancer and Its Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1379.	1.8	8
480	In Vivo Profiling with <sup>18</sup> F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. <i>Molecular Pharmaceutics</i> , 2022, 19, 704-709.	2.3	2
481	Optical Nanopore Sensors for Quantitative Analysis. <i>Nano Letters</i> , 2022, 22, 869-880.	4.5	19
482	Malignant pleural effusions for cancer genotyping: A matter of trans-pleural traffic of cell-free tumor DNA. <i>Molecular and Cellular Probes</i> , 2022, 61, 101793.	0.9	1
483	Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells. <i>Annals of Hematology</i> , 2022, 101, 811-824.	0.8	7
484	Recent advances in liquid biopsy technologies for cancer biomarker detection. <i>Sensors &amp; Diagnostics</i> , 2022, 1, 343-375.	1.9	15
485	Research Progress of Circulation Cell-Free DNA in Clinical Diseases. <i>Advances in Clinical Medicine</i> , 2022, 12, 1446-1454.	0.0	0
486	Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR TKIs in a real-world clinical setting. <i>Molecular and Clinical Oncology</i> , 2022, 16, 88.	0.4	1
487	Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00487.	1.3	10
488	Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 2836-2843.	0.3	1

#	ARTICLE	IF	CITATIONS
489	Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102362.	3.4	33
490	Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 2834-2841.	0.3	0
491	Saliva Based Liquid Biopsies in Head and Neck Cancer: How Far Are We From the Clinic?. <i>Frontiers in Oncology</i> , 2022, 12, 828434.	1.3	29
492	Overexpression of the miR-143/145 and reduced expression of the let-7 and miR-126 for early lung cancer diagnosis. <i>Journal of Applied Biomedicine</i> , 2022, 20, 1-6.	0.6	7
493	Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1169-1181.	0.9	5
494	Serial monitoring of genomic alterations in circulating tumor cells of ER $\alpha$ -positive/HER2 $\alpha$ -negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2022, 16, 1969-1985.	2.1	8
495	Cancer Type Classification in Liquid Biopsies Based on Sparse Mutational Profiles Enabled through Data Augmentation and Integration. <i>Life</i> , 2022, 12, 1.	1.1	15
496	Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188729.	3.3	13
500	Diagnostic and therapeutic biomarkers in colorectal cancer: a review.. <i>American Journal of Cancer Research</i> , 2022, 12, 661-680.	1.4	0
501	Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis. <i>Oncolmmunology</i> , 2022, 11, 2067944.	2.1	12
502	Gold Nanoparticles Based Optical Biosensors for Cancer Biomarker Proteins: A Review of the Current Practices. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 877193.	2.0	14
503	Extracellular DNA Traps: Origin, Function and Implications for Anti-Cancer Therapies. <i>Frontiers in Oncology</i> , 2022, 12, 869706.	1.3	9
504	New Insights into Adjuvant Therapy for Localized Colon Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	1
505	Circulating Tumor DNA in Pediatric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	1
506	Potential clinical utility of liquid biopsies in ovarian cancer. <i>Molecular Cancer</i> , 2022, 21, 114.	7.9	51
507	Tuning particle inertial separation in sinusoidal channels by embedding periodic obstacle microstructures. <i>Lab on A Chip</i> , 2022, 22, 2789-2800.	3.1	24
510	Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. <i>Journal of Clinical Oncology</i> , 2022, 40, 3047-3056.	0.8	19
511	Multiple roles of circulating tumor cells and exosomes in cancer metastasis. , 2022, , 7-21.		0

#	ARTICLE	IF	CITATIONS
512	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analytes?. <i>Laboratoriums Medizin</i> , 2022, 46, 255-264.	0.1	6
513	Circulating tumor cells in neuroblastoma: Current status and future perspectives. <i>Cancer Medicine</i> , 2023, 12, 7-19.	1.3	4
514	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 1394-1402.	2.9	25
515	Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. <i>European Journal of Cancer</i> , 2022, 171, 44-54.	1.3	14
516	Circulating cancer biomarkers: current status and future prospects. , 2022, , 409-443.		0
517	Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2022, 18, 26.	0.1	0
518	Ultrasensitive Detection of Exosomes Using an Optical Microfiber Decorated with Plasmonic MoSe <sub>2</sub> -Supported Gold Nanorod Nanointerfaces. <i>ACS Sensors</i> , 2022, 7, 1926-1935.	4.0	11
519	Predictive biomarkers for personalized medicine in breast cancer. <i>Cancer Letters</i> , 2022, 545, 215828.	3.2	14
520	Isolation of circulating tumor cells. <i>IScience</i> , 2022, 25, 104696.	1.9	20
521	Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
522	Recent advances in nanotechnology and microfluidic-based approaches for isolation and detection of circulating tumor cells (CTCs). <i>Nano Structures Nano Objects</i> , 2022, 31, 100886.	1.9	12
523	Liquid Biopsy – A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer. <i>Proceedings of the Latvian Academy of Sciences</i> , 2022, 76, 325-332.	0.0	0
524	Sequencing of cerebrospinal fluid in non-small cell lung cancer patients with leptomeningeal metastasis: A systematic review. <i>Cancer Medicine</i> , 2023, 12, 2248-2261.	1.3	5
525	Bioplatfoms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. <i>Biotechnology and Genetic Engineering Reviews</i> , 2022, 38, 339-383.	2.4	8
526	Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. <i>Genes and Diseases</i> , 2023, 10, 960-989.	1.5	13
527	Mitochondria dysfunction in circulating tumor cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
528	Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
529	Single cell metabolism: current and future trends. <i>Metabolomics</i> , 2022, 18, .	1.4	11

#	ARTICLE	IF	CITATIONS
530	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 115-132.	0.0	0
531	Identification of Cancer Cells in the Human Body by Anti-Telomerase Peptide Antibody: Towards the Isolation of Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12872.	1.8	1
532	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. <i>Cancers</i> , 2022, 14, 4834.	1.7	0
533	Micro/nanofluidic-electrochemical biosensors for in situ tumor cell analysis. <i>TrAC - Trends in Analytical Chemistry</i> , 2022, 157, 116799.	5.8	5
534	DNA-functionalized covalent organic framework capsules for analysis of exosomes. <i>Talanta</i> , 2023, 253, 124043.	2.9	11
535	Inferring parameters of cancer evolution in chronic lymphocytic leukemia. <i>PLoS Computational Biology</i> , 2022, 18, e1010677.	1.5	3
536	Latest updates on cellular and molecular biomarkers of gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
537	Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211439.	1.4	3
538	Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	12
539	Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. <i>Clinical Cancer Research</i> , 2023, 29, 899-909.	3.2	14
540	High-purity isolation platelets by gradient centrifugation plus filtration. <i>International Journal of Laboratory Hematology</i> , 2023, 45, 187-194.	0.7	1
541	A clinical prognostic model for patients with esophageal squamous cell carcinoma based on circulating tumor DNA mutation features. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
542	Isolation, Detection and Analysis of Circulating Tumour Cells: A Nanotechnological Bioscope. <i>Pharmaceutics</i> , 2023, 15, 280.	2.0	2
543	Integrating Cutting-Edge Methods to Oral Cancer Screening, Analysis, and Prognosis. <i>Critical Reviews in Oncogenesis</i> , 2023, 28, 11-44.	0.2	2
544	Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. <i>Pathology Research and Practice</i> , 2023, 245, 154455.	1.0	1
545	Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data. <i>Seminars in Cancer Biology</i> , 2023, 92, 61-73.	4.3	2
546	Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 41-51.	1.5	1
547	Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. <i>Molecular Cancer</i> , 2023, 22, .	7.9	12

#	ARTICLE	IF	CITATIONS
548	Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4238.	1.8	16
549	Increasing the Capture Rate of Circulating Tumor DNA in Unaltered Plasma Using Passive Microfluidic Mixer Flow Cells. <i>Langmuir</i> , 2023, 39, 3225-3234.	1.6	1
550	Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma. <i>Current Oncology</i> , 2023, 30, 2781-2791.	0.9	2
551	Cancer Diagnostics. , 2023, , 459-481.		0
552	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 102-138.	0.5	14
553	Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2023, 23, 339-349.	1.1	1
554	Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis. <i>Frontiers in Surgery</i> , 0, 10, .	0.6	1
555	Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
556	Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
557	Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	1
558	Single-Cell Enzymatic Screening for Epithelial Mesenchymal Transition with an Ultrasensitive Superwetting Droplet-Array Microchip. <i>Small Methods</i> , 2023, 7, .	4.6	0
561	Fabrication of Multilayer Microfluidic Arrays for Passive, Efficient DNA Trapping and Profiling. <i>Methods in Molecular Biology</i> , 2023, , 315-322.	0.4	0
572	A review of acoustofluidic separation of bioparticles. <i>Biophysical Reviews</i> , 0, , .	1.5	2
585	Colorectal cancer: understanding of disease. , 2024, , 1-27.		0
590	Krebsdiagnostik. , 2024, , 525-551.		0
594	Plasmonic Nanobiosensors for Early Diagnosis of Cancers. , 2024, , 1-49.		0